[go: up one dir, main page]

WO2003105903A1 - Composition medicinale fongicide - Google Patents

Composition medicinale fongicide Download PDF

Info

Publication number
WO2003105903A1
WO2003105903A1 PCT/JP2003/007366 JP0307366W WO03105903A1 WO 2003105903 A1 WO2003105903 A1 WO 2003105903A1 JP 0307366 W JP0307366 W JP 0307366W WO 03105903 A1 WO03105903 A1 WO 03105903A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
antifungal
composition according
antifungal pharmaceutical
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2003/007366
Other languages
English (en)
Japanese (ja)
Inventor
円 伊藤
英明 笹川
中島　琢自
野沢　暁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pola Orbis Holdings Inc
Original Assignee
Pola Chemical Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pola Chemical Industries Inc filed Critical Pola Chemical Industries Inc
Priority to JP2004512803A priority Critical patent/JPWO2003105903A1/ja
Priority to AU2003242235A priority patent/AU2003242235A1/en
Publication of WO2003105903A1 publication Critical patent/WO2003105903A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Definitions

  • the present invention relates to a pharmaceutical composition, and more particularly, to a pharmaceutical composition useful for treating or preventing mycosis.
  • an antifungal pharmaceutical composition by combining an antifungal compound with a specific film-forming agent or a solid or paste-like water-soluble plasticizer at 20 ° C at 1 atm. It is not known at all that the antifungal pharmaceutical composition having the composition is useful for treating mycosis in tinea unguium, hyperkeratosis, and skin hyperplasia. Disclosure of the invention The present invention has been made under such circumstances, and it is an object of the present invention to provide a pharmaceutical composition useful for topical treatment of mycosis that has reached the bottom of thick keratin.
  • the present invention is as follows.
  • the water-insoluble or water-insoluble film-forming agent is one or more selected from the group consisting of ethylcellulose, hydroxypropylmethylcellulose phthalate, and acryl resin emulsion.
  • the water-soluble plasticizer in the form of a solid or a paste at a pressure of 20 ° C. is a compound having a polyoxyethylene group and a Z or polyoxypropylene group,
  • the antifungal pharmaceutical composition according to any one of (1) to (4).
  • the antifungal pharmaceutical composition according to (5), wherein the water-soluble plasticizer in the form of a solid or a paste at a pressure of 20 ° C. is a oxyethylene oxypropylene copolymer.
  • the antifungal compounds are terbinafine, butenafine, bifonazole, fluconazo mono / re, itraconazo monole, clotrimazonole, pentaclonolepheno / le, triclonolenoenole force, proate, trifluoromenoenole force.
  • the antifungal pharmaceutical composition of the present invention comprises: 1) a film-forming agent; 2) a water-soluble plasticizer in the form of a solid or paste at 1 atm. 20 ° C .; 3) an antifungal compound and / or its physiologically acceptable. And a salt.
  • the film-forming agent contained in the antifungal pharmaceutical composition of the present invention those which are usually used in pharmaceutical compositions and the like, and those which are insoluble or poorly soluble in water can be preferably exemplified.
  • insoluble or poorly soluble in water means, for example, those having a saturated concentration in water at 20 ⁇ 5 ° C. of about 1 g / 10 L, preferably about 1 g / 50 L or less.
  • Examples of such a film-forming agent include alkylcellulose represented by ethylcellulose ⁇ hydroxypropylmethylcellulose phthalate, and Eudragit (registered trademark) NE30D which is a dispersion of ethyl acrylate / methyl methacrylate copolymer.
  • alkylcellulose represented by ethylcellulose ⁇ hydroxypropylmethylcellulose phthalate
  • Eudragit (registered trademark) NE30D which is a dispersion of ethyl acrylate / methyl methacrylate copolymer.
  • Preferred examples include acryl resin emulsions such as those marketed by Higuchi Shokai. These can be used solely or in combination of two or more. Of these, particularly preferred is the use of ethyl cellulose alone.
  • the content of the film-forming agent in the antifungal pharmaceutical composition of the present invention is preferably 0.1 to 10% by weight, more preferably 0.3 to 10% by weight, based on the total amount of the pharmaceutical composition. 5% by weight to volume. This is because if the amount of the film-forming agent is too small, a film having sufficient strength may not be obtained, and if the amount is too large, the transfer of the drug may be inhibited.
  • Examples of the water-soluble plasticizer which is contained in the pharmaceutical composition of the present invention in the form of a solid or a paste at a pressure of 20 ° C. and a pressure of 20 ° C. include polymers or copolymers of oxyalkylene such as oxyethylene and oxypropylene, More preferably, the polymerization degree is large.
  • the oxyalkylene is preferably one having 1 to 4 carbon atoms, and more preferably oxyethylene and Z or oxypropylene.
  • the preferable degree of polymerization of the polyoxyalkylene is preferably 70 or more in total, especially at least 80 or more if only oxyethylene, and at least 70 or more if only oxypropylene, and a combination of oxyethylene and oxypropylene.
  • the propylene is 30 to 80 and the oxyethylene is 35 to
  • the condition is 400, and the sum of both is 70 or more.
  • More preferred is a copolymer having oxyethylene and oxypyrene, with a polyoxyethylene chain having a polymerization degree of 100 to 300, and a polyoxypropylene chain having a polymerization degree of 25 to 80. Things.
  • the oxyalkylene polymer or copolymer may contain only one kind or two or more kinds in combination. However, when two or more kinds are combined, the mixture of such combinations also needs to maintain a solid or paste state at 1 atmosphere and 20 ° C.
  • a particularly preferable combination is a polyoxyethylene part having a degree of polymerization of 140 to 180, and a polyoxypropylene part having a degree of polymerization of 20 to 40. It is a copolymer having only oxyethylene polyoxypropylene ether.
  • the content of the plasticizer in the antifungal pharmaceutical composition of the present invention is preferably from 1 to 10% by weight, more preferably from 3 to 8% by weight, based on the total amount of the pharmaceutical composition. It is. Further, the content of the film forming agent is preferably 1 to 10 times, more preferably 3 to 8 times.
  • the antifungal compound contained in the present invention exerts an antifungal action against fungi causing dermatomycosis or deep mycosis, for example, disease-causing fungi such as mentagrophyte or Candida. It can be used without any particular limitation if it exists, for example,
  • R is an alkyl group having 1 to 8 carbon atoms, a cycloalkyl group having 3 to 6 carbon atoms, a methylene group, a lower alkenyl group, a halogen atom, a lower alkoxy group, a lower Represents a lower alkyl group substituted with a alkylthio group, or a group represented by the following general formula (2).
  • a hydrogen atom, a halogen atom, a linear or branched lower alkyl group, a lower alkoxy group, a haloalkoxy group, or a methylenedioxy group is shown, and m represents an integer of 1 to 3.
  • antifungal compounds contained in the present invention include terbinafine (compound 1), butenafine (compound 2), bifonazole (compound 3), fluconazo mono (compound 4), traconazonole, black trimazonole, pentaclonolef Enol, trichlorophenol caproate, tribromophenol caproate, lauryltriphenylphosphonium bromide, diantazole hydrochloride, paraacetylaminophenylrodane, thimerosal, pendecylenic acid, zinc decylenate, de / remacide, barium thiamine Mononorethrin, sicanin, miconazonole, econazo monole, isoconazonole, snoreconazo monole, choconazole, oxyconazo monole, ketoconazole, cyclopyroxolamine, Rushikureto, Nafuti fins
  • physiologically acceptable salts are not particularly limited as long as they are physiologically acceptable.
  • minerals such as hydrochloride, nitrate, sulfate, phosphate, etc.
  • Organic acid salts such as citrate and acetate, and sulfates such as mesylate and tosylate can be preferably exemplified.
  • Hydrochloride is more preferred in terms of safety and solubility.
  • the antifungal compound of the present invention and / or a physiologically acceptable salt thereof uses only one species. Can be used, or two or more kinds can be used in combination.
  • Anti antifungal compounds in fungi pharmaceutical composition and / or preferred content of physiologically acceptable salts of the present invention is 0 in total with respect to the total amount of the pharmaceutical composition. 1-3 0 weight to volume 0/0 And more preferably 0.5 to 15% by weight to volume. The amount of the antifungal compound may be determined in consideration of the relationship with the properties of the film to be formed.
  • the pharmaceutical composition of the present invention may contain, in addition to the above essential components, any components usually used in external preparations for skin and the like. Can be contained.
  • hydrocarbons such as petrolatum and microcrystalline wax, esthetics such as jojoba oil and gay wax, triglycerides such as tallow, olive oil, and higher alcohols such as cetanol and oleyl alcohol.
  • Fatty acids such as stearic acid and oleic acid, alcohols such as ethanol and isopropanol, polyhydric alcohols such as glycerin and 1,3-butanediol, water, nonionic surfactants, and ionic surfactants
  • examples thereof include cationic surfactants, amphoteric surfactants, thickeners such as ethanol and carbopol, preservatives, ultraviolet absorbers, antioxidants, dyes, powders, and organic solvents.
  • compositions of the present invention are anionic surfactants and organic solvents.
  • Anionic surfactants have the effect of promoting the penetration of drugs into nails or the inside of hardened skin, and are preferred in this sense. These ayuon surfactants can be used alone or in combination of two or more.
  • any of a sulfated aionic surfactant and a phosphoric acid-based surfactant can be used, and may or may not have a polyoxyethylene resin.
  • alkyl sulfates which may have polyoxyethylene groups and alkyl phosphates which may have Z or polyoxyethylene groups.
  • alkyl sulfates and Z or polyoxyethylene-added alkyl triphosphates are particularly preferably from 2 to 16.
  • the alkyl group preferably has 10 to 20 carbon atoms, specifically, a lauryl group, a palmityl group or Is preferably a stearyl group.
  • a form containing both lauryl sulfate and tripolyoxyethylene (also referred to as tri-POE) (4) lauryl ether phosphate can be exemplified.
  • the salts of these anionic surfactants include, for example, alkaline metal salts such as sodium phosphate, organic amine salts such as monoethanolamine, triethanolamine, and triethylamine, and ammonium salt; Preferable examples include salts of basic amino acids such as arginine and lysine, among which alkali metal salts are preferable, and sodium salts are particularly preferable.
  • the content of the above-mentioned aeon surfactant is preferably 0.5 to 10% by weight based on the total amount of the pharmaceutical composition. /. And more preferably 1 to 5% by weight to volume. Further, a form in which 1 to 5 parts by weight of lauryl sulfate and 0.5 to 3 parts by weight of triPOE (4) lauryl ether phosphate are contained in 100 parts by volume of the antifungal pharmaceutical composition of the present invention. It can be preferably exemplified.
  • the pharmaceutical composition of the present invention can be produced by treating the above essential components and optional components according to a conventional method.
  • composition of the present invention forms a plastic film when applied to an application object.
  • This coating shows a viscous glassy state. More specifically, the coating itself is a solid, but the internal components are moving.
  • This film is a film that can be applied repeatedly.
  • the pharmaceutical composition is administered again to form a film for the purpose of continuing treatment, the previously applied and dried film inhibits the transfer of the newly applied film to the affected area of the drug. There is no.
  • the pharmaceutical composition of the present invention when applied to the affected area of nails or skin, unlike a commonly known lacquer preparation, this coating is not usually peeled off, but is removed by swelling with an aqueous solvent and physical scraping. it can. Specifically, if a surface active agent such as soap is added and rubbed as desired in a humidified state of water or the like, the coating of the pharmaceutical composition of the present invention can be easily removed.
  • the coating is in a glassy state, the drug easily moves from the coating to the affected area, so that the coating is always supplied to the affected area at a constant concentration.
  • the dosage form of the antifungal pharmaceutical composition for external use is difficult to obtain the effect of administering the drug, and it is also used externally and effectively for the treatment of mycosis in the hyperkeratotic part of the skin or the thickened part of the foot margin. be able to. Therefore, the antifungal pharmaceutical composition of the present invention can be used for affected areas such as nails, keratinized areas of the skin, or skin thickened areas around the feet.
  • the fungi to be used in the antifungal pharmaceutical composition of the present invention include Trichophyton (Trichophyton), a causative agent of candidiasis (Candida), and a causative fungus of Cryptosporidium disease (Taliptos). Polyspermia) or yeasts (Aspergillus). .
  • the pharmaceutical composition of the present invention can be produced by a usual method.
  • the preferred production examples are as follows.
  • the antifungal compound Selected from the group consisting of methylcellulose phthalate and acrylonitrile emulsion 1
  • One or more species are added and dissolved, and the antifungal compound and / or a physiologically acceptable salt thereof are added and dissolved.
  • the antifungal compound can be formulated with high stability without crystal precipitation even in a water-containing solvent.
  • a preferable production method of the antifungal pharmaceutical composition of the present invention can be provided.
  • Punorelloek F-68 Polyoxyethylene (160) poly
  • Macrogonere 400 Polyethylene glycolone 400
  • an antifungal pharmaceutical composition of the present invention was produced.
  • the component a was solubilized by stirring, the component b was added to solubilize it, the component c was further added and solubilized, and then the component d was added. Subsequently, e was added to adjust the total amount to 10 OmL, thereby obtaining an antifungal pharmaceutical composition.
  • compositions of comparative techniques which do not belong to the antifungal pharmaceutical composition of the present invention were prepared using components a to e in the same order as in Example 1. (Comparative Example 1 did not have b and Comparative Example 3 did not have c.) 0307366
  • Example 3 so that the total volume is 0 mL per day
  • the nail scraps were spread on a Sabouraud agar medium and cultured at 28 ° C for 143 to confirm the growth of the bacteria. Nails where no bacterial growth was observed were considered bacterial negative. The percentage of nail debris that was negative for bacteria was calculated. Table 7 shows the results.
  • the antifungal pharmaceutical composition of the present invention is excellent in fungal diseases which are difficult to treat by external application because of its excellent drug storing properties and drug releasing properties, which are prevented by thick keratin such as nails. It is evident that it has an effect.
  • Table 7
  • An antifungal pharmaceutical composition of the present invention was prepared according to the formulation shown in Table 8 below in the same manner as in Example 1.
  • the drying time was 45 seconds
  • the state of the film 12 hours after application was ⁇
  • the detergency with water was ⁇ .
  • a composition of Comparative Example 4 not belonging to the antifungal pharmaceutical composition of the present invention was produced in the same manner as in Example 1.
  • the drying time was 45 seconds
  • the state of the film 12 hours after application was X
  • the detergency with water was ⁇ .
  • the antifungal pharmaceutical composition of the present invention was prepared in the same manner as in Example 1 according to the formulation shown in Table 10 below. When this was evaluated according to the method of Example 3, the drying time was 40 seconds, the state of the film 12 hours after application was ⁇ , and the detergency with water was ⁇ . Table 10 Components
  • the pharmaceutical composition useful for external treatment of the mycosis which reached the lower part of thick keratin can be provided.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition médicinale antimycosique agissant, en application externe, en direction des zones situées sous la couche de cornée épaisse. L'invention concerne plus particulièrement une composition médicinale antimycosique contenant: 1) un filmogène, 2) un plastifiant hydrosoluble à consistance solide ou pâteuse à 20°C sous 1 atm, et 3) un fongicide et/ou l'un de ses sels physiologiquement acceptables.
PCT/JP2003/007366 2002-06-18 2003-06-10 Composition medicinale fongicide Ceased WO2003105903A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2004512803A JPWO2003105903A1 (ja) 2002-06-18 2003-06-10 抗真菌医薬組成物
AU2003242235A AU2003242235A1 (en) 2002-06-18 2003-06-10 Antifungal medicinal composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002-177061 2002-06-18
JP2002177061 2002-06-18

Publications (1)

Publication Number Publication Date
WO2003105903A1 true WO2003105903A1 (fr) 2003-12-24

Family

ID=29728136

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/007366 Ceased WO2003105903A1 (fr) 2002-06-18 2003-06-10 Composition medicinale fongicide

Country Status (3)

Country Link
JP (1) JPWO2003105903A1 (fr)
AU (1) AU2003242235A1 (fr)
WO (1) WO2003105903A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006042324A3 (fr) * 2004-10-12 2006-06-15 Qlt Usa Inc Composition pharmaceutique pouvant etre appliquee a un tissu corporel
WO2007039533A2 (fr) 2005-09-29 2007-04-12 Novartis Ag Composition antifongique
WO2007064181A1 (fr) * 2005-11-30 2007-06-07 Fernando Ahumada Ayala Preparations de soin des ongles contenant du chlorydrate de terbinafine
WO2018110693A1 (fr) 2016-12-16 2018-06-21 株式会社カネカ Agent thérapeutique contre l'onychomycose
WO2019240212A1 (fr) * 2018-06-14 2019-12-19 株式会社カネカ Formulation contenant un ingrédient pharmaceutiquement actif

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07126164A (ja) * 1993-10-29 1995-05-16 Taisho Pharmaceut Co Ltd 持効性抗真菌剤
US5438076A (en) * 1988-05-03 1995-08-01 Perio Products, Ltd. Liquid polymer composition, and method of use
WO1995025544A1 (fr) * 1994-03-21 1995-09-28 John Brown Thomsen Gel destine au traitement des maladies de la peau et a la desinfection de celle-ci
WO1997002821A2 (fr) * 1995-07-08 1997-01-30 Nihon Nohyaku Co., Ltd. Agent antifongique, son compose, son procede de production
WO1998013042A1 (fr) * 1996-09-27 1998-04-02 Hoechst Aktiengesellschaft Gel antimycotique a forte liberation de principe actif
EP0848003A1 (fr) * 1996-12-10 1998-06-17 Nihon Nohyaku Co., Ltd. Dérivés de (R)-(E)-(4-substitué phenyl-1,3-dithiolan-2-ylidène)-1-imidazolylacetonitrile optiquement actifs et leur utilisation comme fongicides
JPH10226639A (ja) * 1996-12-10 1998-08-25 Shiseido Co Ltd 被膜形成性抗真菌剤組成物
WO1999049835A1 (fr) * 1998-03-31 1999-10-07 Johnson And Johnson Consumer Companies, Inc. Composition acidifiee pour le traitement topique d'affections ungeales et cutanees
JP2000186037A (ja) * 1998-10-16 2000-07-04 Fujisawa Pharmaceut Co Ltd 持続性外用抗真菌剤
WO2001012155A1 (fr) * 1999-08-17 2001-02-22 Lipocine, Inc. Compositions et procedes d'absorption amelioree d'agents therapeutiques hydrophiles
WO2001037890A1 (fr) * 1999-11-23 2001-05-31 Ever Power Holding Inc Composition transdermique sans propulseurs appliquee par pulverisation, destinee a favoriser la cicatrisation et a administrer des medicaments
WO2001062195A1 (fr) * 2000-02-24 2001-08-30 Advancis Pharmaceutical Corporation Compositions antibiotiques et antifongiques
EP1138314A2 (fr) * 2000-03-27 2001-10-04 Taro Pharmaceutical Industries Ltd Système de libération controlée d'agents antimycotiques et kératolitiques pour le traitement local des infections fongiques des ongles et des tissus voisins
JP2002053462A (ja) * 2000-08-10 2002-02-19 Pola Chem Ind Inc 抗真菌医薬組成物
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5438076A (en) * 1988-05-03 1995-08-01 Perio Products, Ltd. Liquid polymer composition, and method of use
JPH07126164A (ja) * 1993-10-29 1995-05-16 Taisho Pharmaceut Co Ltd 持効性抗真菌剤
WO1995025544A1 (fr) * 1994-03-21 1995-09-28 John Brown Thomsen Gel destine au traitement des maladies de la peau et a la desinfection de celle-ci
WO1997002821A2 (fr) * 1995-07-08 1997-01-30 Nihon Nohyaku Co., Ltd. Agent antifongique, son compose, son procede de production
WO1998013042A1 (fr) * 1996-09-27 1998-04-02 Hoechst Aktiengesellschaft Gel antimycotique a forte liberation de principe actif
JPH10226639A (ja) * 1996-12-10 1998-08-25 Shiseido Co Ltd 被膜形成性抗真菌剤組成物
EP0848003A1 (fr) * 1996-12-10 1998-06-17 Nihon Nohyaku Co., Ltd. Dérivés de (R)-(E)-(4-substitué phenyl-1,3-dithiolan-2-ylidène)-1-imidazolylacetonitrile optiquement actifs et leur utilisation comme fongicides
WO1999049835A1 (fr) * 1998-03-31 1999-10-07 Johnson And Johnson Consumer Companies, Inc. Composition acidifiee pour le traitement topique d'affections ungeales et cutanees
JP2000186037A (ja) * 1998-10-16 2000-07-04 Fujisawa Pharmaceut Co Ltd 持続性外用抗真菌剤
WO2001012155A1 (fr) * 1999-08-17 2001-02-22 Lipocine, Inc. Compositions et procedes d'absorption amelioree d'agents therapeutiques hydrophiles
WO2001037890A1 (fr) * 1999-11-23 2001-05-31 Ever Power Holding Inc Composition transdermique sans propulseurs appliquee par pulverisation, destinee a favoriser la cicatrisation et a administrer des medicaments
WO2001062195A1 (fr) * 2000-02-24 2001-08-30 Advancis Pharmaceutical Corporation Compositions antibiotiques et antifongiques
EP1138314A2 (fr) * 2000-03-27 2001-10-04 Taro Pharmaceutical Industries Ltd Système de libération controlée d'agents antimycotiques et kératolitiques pour le traitement local des infections fongiques des ongles et des tissus voisins
JP2002053462A (ja) * 2000-08-10 2002-02-19 Pola Chem Ind Inc 抗真菌医薬組成物
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006042324A3 (fr) * 2004-10-12 2006-06-15 Qlt Usa Inc Composition pharmaceutique pouvant etre appliquee a un tissu corporel
NO339414B1 (no) * 2005-09-29 2016-12-12 Novartis Ag Soppdrepende preparat
WO2007039533A3 (fr) * 2005-09-29 2007-08-09 Novartis Ag Composition antifongique
JP2009510023A (ja) * 2005-09-29 2009-03-12 ノバルティス アクチエンゲゼルシャフト 抗真菌組成物
AU2006298748B2 (en) * 2005-09-29 2010-06-03 Karo Healthcare AB Antifungal composition
WO2007039533A2 (fr) 2005-09-29 2007-04-12 Novartis Ag Composition antifongique
WO2007064181A1 (fr) * 2005-11-30 2007-06-07 Fernando Ahumada Ayala Preparations de soin des ongles contenant du chlorydrate de terbinafine
WO2018110693A1 (fr) 2016-12-16 2018-06-21 株式会社カネカ Agent thérapeutique contre l'onychomycose
CN110087652A (zh) * 2016-12-16 2019-08-02 株式会社钟化 甲癣治疗剂
JPWO2018110693A1 (ja) * 2016-12-16 2019-10-24 株式会社カネカ 爪白癬治療剤
WO2019240212A1 (fr) * 2018-06-14 2019-12-19 株式会社カネカ Formulation contenant un ingrédient pharmaceutiquement actif
CN112368023A (zh) * 2018-06-14 2021-02-12 株式会社钟化 包含药物活性成分的制剂
JPWO2019240212A1 (ja) * 2018-06-14 2021-06-24 株式会社カネカ 薬学的活性成分を含む製剤
US12042540B2 (en) 2018-06-14 2024-07-23 Kaneka Corporation Formulation comprising active pharmaceutical ingredient

Also Published As

Publication number Publication date
JPWO2003105903A1 (ja) 2005-10-13
AU2003242235A1 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
US8741941B2 (en) Antifungal medicinal compositions
JP3527749B2 (ja) 医薬組成物
CA2341814C (fr) Dispositif d'administration d'agents antifongiques et keratolytiques pour le traitement local d'infections fongiques de l'ongle et des tissus avoisinants
JP2011500779A (ja) 新規製剤
JP2007534764A (ja) 抗真菌薬物送達
WO2010124237A1 (fr) Méthodes de traitement d'infections unguéales
WO2003105903A1 (fr) Composition medicinale fongicide
EP1931309B1 (fr) Composition antifongique
KR101799008B1 (ko) 케라틴 조직의 진균감염증 치료를 위한 약제학적 조성물
KR101690765B1 (ko) 항진균성 활성물질을 포함하는 경피 제제
JP2002053462A (ja) 抗真菌医薬組成物
JP2025510868A (ja) ミラベグロン製剤
JP5059408B2 (ja) 爪用外用剤
JP2006501223A (ja) 真菌感染を治療する方法
JP3000490B2 (ja) 抗白癬菌剤
US8257688B2 (en) Controlled delivery system of antifungal and keratolytic agents for local treatment of fungal infections of the nail and surrounding tissues
KR20120056314A (ko) 테르비나핀 또는 그의 염을 함유하는 국소 항진균 조성물
RU2238092C2 (ru) Водная лекарственная композиция для лечения заболеваний кожи
CN101262848A (zh) 抗真菌组合物
JPS6261929A (ja) 水溶性薬物の経皮吸収性を高めた皮膚外用剤
HK1117403B (en) Antifungal composition
SA92130074B1 (ar) تركيبة صيدليه محتوية تيربينافين Terbenafing كعامل ضد الفطر agentanti-mycostic

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004512803

Country of ref document: JP

122 Ep: pct application non-entry in european phase